A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas
Current Oncology · 2025
DOI: 10.3390/curroncol32090516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Dan-Thanh Christine Nguyen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Standard systemic treatment has not been established for refractory meningioma. This retrospective study aimed to identify prognostic factors for overall survival and document outcomes of systemic therapies. We reviewed patients with meningioma followed at CHUM hospital between 2006 and 2022. Only patients with progression after first-line treatment were included. Among 750 patients, 107 (14%) experienced progression after first-line treatment. They were divided into two groups: Group 1 (n = 69, 64%) received salvage local treatments, and Group 2 (n = 38, 36%) received additional salvage systemic treatments. The median follow-up time from diagnosis was 7.5 years. 10-year OS was 88.3% (Group 1) vs. 67.2% (Group 2) (p = 0.009). Mean survival after stopping systemic treatment was 8.94 months. Key prognostic factors for poorer survival included age ≥ 65 (HR = 2.82; p = 0.009), WHO grade 2 or 3 (HR = 4.25; p = 0.004), and progression after second-line treatment (HR = 4.77; p = 0.004). Bevacizumab was associated with a mPFS of 12 months and 1-year OS of 64,6%, whereas non-Bevacizumab treatments—including Hydroxyurea, Somatostatin, and Sunitinib—were associated with a mPFS of 7 months and 1-year OS of 52,6%. This study highlights the fatal nature of recurrent meningiomas and the urgent need for systemic treatments that can improve their survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
- Department of Anesthesia, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
- Department of Radio-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
- Department of Neurosurgery, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
- Department of Pathology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
ORCID-Profile: Dan-Thanh Christine Nguyen, Sarah Lapointe, David Roberge, Romain Cayrol
Zitieren
APA
Nguyen, D. C., Nader, C., Bélanger, K., Lapointe, S., Lemieux, B., Lemieux-Blanchard, É., Bahary, J. P., Masucci, L., Lambert, C., Roberge, D., Moumdjian, R., Labidi, M., Cayrol, R., & Florescu, M. (2025). A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas. Current Oncology. https://doi.org/10.3390/curroncol32090516
Vancouver
Nguyen DC, Nader C, Bélanger K, Lapointe S, Lemieux B, Lemieux-Blanchard É, et al. A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas. Current Oncology. 2025. doi:10.3390/curroncol32090516
BibTeX
@article{Nguyen2025,
author = {Nguyen, Dan-Thanh Christine and Nader, Cyril and Bélanger, Karl and Lapointe, Sarah and Lemieux, Bernard and Lemieux-Blanchard, Émilie and Bahary, Jean-Paul and Masucci, Laura and Lambert, Carole and Roberge, David and Moumdjian, Robert and Labidi, Moujahed and Cayrol, Romain and Florescu, Marie},
title = {A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32090516}
}
EUVIMED